Will It Be Possible to Create A Fully Autonomous Store?

Walking into a convenience store is meant to be quick and seamless, but often when a crowd appears, long lines can make shopping tedious and frustrating. The rise of artificial intelligence (AI) has made its way into shopping. CEO and Co-Founder Steve Gu sits down with What Just Happened? Host Christine Russo on the direction of AI in retail.

While the use of e-commerce is growing, many consumers still crave physical spaces, including shopping in stores. “I believe that roughly more than 80% of the transactions still happen in the physical world,” Gu said. “As humans, we still need to interact with physical objects and even though many of us are fans online, myself included the majority of the activities we do still happen in the world, and that’s where we think AI can play a huge role.”

AiFi’s new partnership with the Miami Dolphins and the Detroit Lions allows fans to scan a QR code, a credit card, or an app to tap and pay, then they simply grab their item and go back to their intended viewing. “I want them to leave as quickly as possible like a Google search engine because I know their goal is to come and leave so they can focus on their game. And in the end, we want a fully autonomous store, or a shop that can run essentially by itself,” Gu said.

The beauty of AiFi, Gu further explained is that they partner with retailers, they do not compete with them. “We are a technology firm by heart. We’re not retailers but we chose to work with retailers to make all this amazing shopping experience happen because we know the future is in AI,” he said.

AiFi plans to fit its products into more local mom-and-pop stores and other venues around the world. “The best part of our system is that we can support different types of users, all based on the same operating platform. We tailor it to the needs of the client because we are flexible to work with, and we want to provide solutions,” Gu said.

More Stories Like This:

Introducing “What Just Happened?” with Christine Russo

AI is Driving Market Personalization

Follow us on social media for the latest updates in B2B!

Image

Latest

ESA
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
April 21, 2025

As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…

Read More
supply chain data analytics
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
April 21, 2025

Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…

Read More
cancer immunotherapy
What’s Next in Preclinical Cancer Immunotherapy Research?
April 19, 2025

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

Read More
vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More